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Abstract
Background: Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematological malignancies.
In MDS patients with a fibrotic bone marrow the aspiration of cells often fails (dry-tap), which hampers standard
karyotyping. Obtaining genetic data from these fibrotic marrows is therefore challenging, and up till now in situ
hybridization applied to bone marrow biopsies is the only option. The microarray-based genomic profiling technology
has already proven its value for bone marrow aspirates and peripheral blood samples, but has never been applied to
the technically challenging bone marrow biopsies. We describe an approach for microarray-based genomic profiling on
bone marrow biopsies and demonstrate its ability to obtain clinically relevant cytogenetic aberrations. In addition the
data were compared with those obtained by in situ hybridization and karyotyping.
Results: We have evaluated the success rate of microarray-based genomic profiling by studying twenty-one bone
marrow biopsies (7 fibrotic MDS, 12 non-fibrotic MDS and 2 reactive), by microarray-based genomic profiling and
in situ hybridization (12 of 21 cases). The data obtained with these techniques were compared with conventional
karyotyping data on corresponding bone marrow aspirates. Of the 15 copy number aberrations that were detected
by in situ hybridization, 13 were concordant with microarray-based genomic profiling and karyotyping, whereas
two hybridizations were misinterpreted. In 20 of 21 patients, the data obtained by microarray-based genomic profiling
and karyotyping were identical or differences could be explained by the presence of marker chromosomes, complex
karyotypes, clonal heterogeneity or disease progression.
Conclusions: We demonstrate that genome wide microarray-based genomic profiling performed on bone marrow
biopsies has a similar success rate compared to in situ hybridization, and prevents misinterpretation of chromosomal
losses as observed by FISH. In addition, equal to even higher resolutions were obtained with genomic profiling
compared to conventional karyotyping. Our findings indicate that microarray-based profiling, even on bone marrow
biopsies, is a valid approach for the identification of genetic abnormalities. This is a valuable substitution in cases of
fibrotic MDS lacking cytogenetic results.
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Background
Myelodysplastic syndrome (MDS) is a heterogeneous
group of hematopoietic neoplasms characterized by
bone marrow dysplasia and ineffective hematopoiesis
which causes peripheral cytopenias and a risk of pro-
gression to acute myeloid leukemia (AML). The diag-
nosis and classification of MDS is based largely on
clinicopathological, morphological and cytogenetic find-
ings. In addition, chromosomal abnormalities are found
in 40-60% of the patients and prove helpful for deter-
mination of prognostic status with regard to survival
and AML evolution [1,2]. For instance in the Inter-
national Prognostic Scoring System (IPSS) for MDS,
cytogenetic subgroups of outcome were defined as
follows: “good” outcomes were associated with a normal
karyotype, −Y alone, del (5q) alone, del (20q) alone;
“poor” outcomes showed complex karyotypes (ie, ≥3
abnormalities) or chromosome 7 anomalies; and “inter-
mediate” outcomes were associated with all other abnor-
malities [1]. Conventional karyotyping is the current
standard screening for chromosomal abnormalities on
metaphases. This approach can be problematic in cases
with fibrotic bone marrow biopsies, often resulting in
none or a non-representative bone marrow aspirate
sample (dry-tap) which does not contain neoplastic
blasts. Such a dry-tap is observed in 4–7% of the bone
marrow examinations [3,4]. In situ hybridization (ISH)
using targeted probes to detect recurrent chromosomal
trisomies and translocations has been applied to bone
marrow biopsies in only a limited number of studies in
MDS [5-8]. The reliable detection of losses of chromo-
somes, and especially loss of chromosome segments is
difficult in tissue sections, since nuclei are generally only
partly present on the slide due to cutting of the tissue,
which may result in false positive identification of
chromosomal losses [5]. In addition, there can be a sig-
nificant intermingling of neoplastic and non-neoplastic
cells in MDS biopsies, resulting in difficulties in the
identification of genetically abnormal neoplastic cells.
The combination of fluorescence in situ hybridization
(FISH) and the detection of immunophenotypic markers
in formalin fixed paraffin-embedded (FFPE) sections of
bone marrow can overcome the problem of a low per-
centage of malignant cells [7].
Genome wide profiling using bacterial artificial chro-
mosome (BAC) libraries, oligonucleotide and single nu-
cleotide polymorphism-based microarray platforms has
been applied in a research or exploratory setting to pro-
file the genomic alterations in patients with MDS and
AML [9-13]. However, these microarray-based genome
profiling approaches have only been applied to high-
molecular weight DNA isolated from bone marrow
aspirates or peripheral blood samples. The experience with
DNA obtained from formalin-fixed paraffin embedded
(FFPE) bone marrow biopsies is very limited, but this
source would be helpful in MDS patients with bone
marrow fibrosis resulting in a non-representative bone
marrow aspirate and subsequent lack of cytogenetic
data. The major disadvantage of DNA from tissue
blocks is the fragmentation and degradation during the
formaldehyde fixation and decalcification process.
To evaluate the diagnostic value of microarray-based
genomic profiling, especially on fibrotic bone marrow
samples, we have compared microarray-based genomic
profiling and FISH or Chromogenic in situ hybridization
on bone marrow biopsies with data obtained by karyo-
typing of corresponding bone marrow aspirate samples
in MDS patients with and without extensive fibrosis in
the bone marrow biopsy. Despite its limitation in detect-
ing (recurrent) balanced translocations and the lower
sensitivity, we demonstrate that, also in patients with a
fibrotic bone marrow, microarray-based genomic profiling
using DNA obtained from bone marrow FFPE-biopsies
has a similar success rate as compared to in situ hybri-
dization applied to bone marrow biopsies. In addition,
microarray-based genomic profiling overcomes the false
positive identification of chromosomal losses that oc-
curred in FISH, can identify genomic abnormalities
which are outside the scope of the ISH probes applied,
and has a comparable or even higher resolution than
karyotyping, since copy number abnormalities > 10 Mb
in size can be easily detected.
Results
Interpretation criteria of microarray data and description
of genomic profiles
Tissues from FFPE trephine biopsy specimens of 24
MDS patients and 2 reactive non-fibrotic cases, all with
a successful cytogenetic result from a simultaneous bone
marrow aspirate, were initially selected. The quality of
the extracted genomic DNA was assessed by its ability
to amplify of control gene fragments of 200 bp or more.
However, three of the 26 FFPE specimens had to be
excluded due to an insufficient quality and/or quantity
of DNA. A microarray-based genomic profile was ob-
tained from genomic DNA from the other 23 patients.
Two additional samples had to be excluded because of
the noise level of the obtained array profiles as measured
by the quality score in Nexus. Therefore, successful
genomic profiling could be performed in 21 of 23 pro-
filed cases (91%). We have divided the patients in three
groups (Table 1). Group 1 consisted of 7 non-fibrotic
MDS cases with cytogenetic abnormalities. Group 2 were
7 MDS cases with availability of an abnormal karyotype
despite bone marrow fibrosis. Group 3 included 4 non-
fibrotic MDS cases, 1 AML case and 2 biopsies of react-
ive bone marrow, all with a normal karyotype except for
a balanced translocation of chromosome 3 in one case.
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Table 1 In situ hybridization, microarray and cytogenetic data of the patients
Group Patient ID Sex Age (years) Diagnosis Fibrosis FISH (BM biopsy) Array based karyotype (BM biopsy) Karyotype (BM aspirate)
1 4902 M 63 RCMD no not done del(16)(q11q23) 46,XY,del(16)(q11q23)[4]/46,XY[6]
4519 F 59 AML no loss 7 (44%) del(3)(p24p22),del(3)(p14p12),del(4)
(p15),dup(5)(p11),del(5)(q11q35),del
(7)(p14p11), del (7)(q11q26),del(10)
(q11q24),del(10)(q25q26),dup(22)(q11)
45,XX,del(5)(q13q33),-7[4]/46,XX[16]
4898 F 42 RCMD no loss 7 (50%) −7,+21,+22 45,XX,-7[4]/47,sl,+21,+22[5]/46,XX[1]
4893 M 80 RAEB-1 no trisomy 8 (50%) +8 47,XY,+8[10]
4895 F 59 RCMD-RS no trisomy 8 (23%) +8 47,XX,+8[6]/46,XX[4]
4896 M 72 RCMD no loss 8 (47%) loss 7 (50%) del(5)(q21q31),-7 44,XY,del(5)(q15q33),-7,dic(15;17)
(p11;p11),-18,der(21;22)(q10;q10),+2mar
[cp8]/46,XY[2]
4912 M 64 RAEB-2 no not done +8,+21 47,XY,+21[1]/48,sl,+8[9]
2 4522 M 57 RCMD grade 3 loss 20q (32%) trisomy 8 (18%) del(3)(p24q25),del(5)(q14q34),del(6)
(p24q16), del(7)(q11q32),+8,del (20)(q11)
40~44,XY,-5,-6,-7,+8,-20,+4mar
[cp7]/46,XY[3]
4894 M 67 RCMD grade 2 loss 20q (77%) del(20)(q11q13) 46,XY,del(20)(q13)[10]
4899 M 58 RAEB grade 3 not done del(2)(p23),del(4)(p12),del(4)(q12q13.2),
del(5)(q14q35),del(7) (q21q36),del(12)
(p12p13),del(20)(q11q13)
44~47,XY,-2,-2,-4,del(4)(q31),-5,-7,add
(9)(q34),add(12)(p13),−13,-15,-16,-17,
add(17)(p13),del(20)(q11),+3~7mar
[cp8]/46,XY[2]
4903 M 58 AML patchy fibrosis faillure no CNA 44~47,XY,-2,-2,-4,-4,+6,-7,-9,-10,-13,-13,-17,
add(17)(p13),−19,del(20)(q11),+21,+21,
+4~8mar[cp8]/46,XY[2]
4523 F 58 RAEB-2 grade 3 loss 7 (46%) loss 5 (29%) del(5)(q14q33),-7 45,XX,t(4;17;20)(q31;q12;q13),del(5)
(q13q33),-7[10]
4520 M 70 RAEB-2 grade 3 loss 7 (61%) loss 5 (40%) -Y,del(5)(q11q34),-7,del(17)(p13),-18 42~44,X,-Y,-5,-7,+?12,-13,add(17)
(p13),-20,-21,+3mar[cp13]
4521 F 59 RCMD grade 2 loss 5q (19%) del(4)(q24q26),del(5)(q13q35),del(6)
(q11q21), del(7)(q11),del (17)(p13.1p13.3)
45~46,XX,add(1)(q32),del(5)(q?22q33),
del(6)(p22),add(7)(q11),-10,-13,del(17)
(p11),+2~3mar[cp10]
3 4904 F 60 RAEB-2 no not done no CNA 46,XX[20]
4906 F 64 vit. B12 deficiency no not done no CNA 46,XX[23]
4897 M 71 hypoplastic AML no not done no CNA 46,XY[20]
4518 F 45 pure red cell aplasia no loss 7q (34%) no CNA 46,XX[20]
4890 M 58 RCMD no not done no CNA 46,XY[20]
4892 F 63 RCMD-RS no not done no CNA 46,XX,t(3;3)(q21;q26)[11]
4900 F 63 RAEB-1 no not done no CNA 46,XX[20]
RCMD = refractory cytopenia with multi lineage dysplasia, RAEB = refractory anemia with excess of blasts, RCMD-RS = RCMD with ringsideroblasts, AML = acute myeloid leukemia, no CNA = no copy number abnormality,
BM = bone marrow.
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For comprehensive analysis and interpretation of the
microarray-based genomic profiling the profiles of the 7
patients without copy number alterations (CNA) as
determined by karyotyping (group 3), were evaluated to
set up the interpretation criteria. In all cases that
fulfilled the quality score in Nexus, small sized aberra-
tions up to 10 Mb in size were observed, which we have
considered as normal genomic variants or background
noise. Therefore the threshold for identification of a
CNA was set at 10 Mb. This threshold is in line with
the resolution of karyotyping. For copy number gains of
chromosome 19 the threshold was set at 30 Mb, since it
has been reported that the high GC content of this
chromosome can result in different amplification effi-
ciency, and that hybridization of the amplified products
can result in erroneously assigned alterations of
chromosome 19 on BAC library-based array-platforms
[14]. Only aberrations fulfilling the above criteria were
included in the genomic profiles. Since MDS samples
can harbor complex patterns of cytogenetic abnor-
malities (≥3 abnormalities) [1,2], the description of the
obtained genomic profiles using the standardized ISCN
2013 [15] nomenclature system may result in complex
reports. Therefore, we have chosen to convert the
genomic array profiles into so-called microarray-
deduced copy number karyotypes, adapted from the
ISCN nomenclature for conventional karyotyping as has
been proposed by Simons at al. [16], thus allowing a
comprehensive comparison of microarray-based gen-
omic profiling data to conventional karyotyping data.
Comparison of microarray-based genomic profiling and in
situ hybridization on bone marrow biopsies
Parallel microarray-based genomic profiling and in situ
hybridizations using relevant probe-sets were applied to
12 of the 21 patients, which covers 15 different probe
hybridizations. For an unbiased comparison the micro-
array and in situ hybridization data were analyzed in a
fully blinded fashion. In four patients (4893, 4895, 4894
and 4523) concordant results were obtained by in situ
hybridization and microarray-based genomic profiling
(Figure 1). In six cases (4519, 4898, 4896, 4522, 4520 and
4521) additional genetic abnormalities were observed by
microarray, while in two cases (4896 and 4518) in situ
hybridization resulted in the identification of an additional
chromosome loss, not observed by microarray and karyo-
typing. In one other case (4903) FISH was unsuccessful
(Table 1). In situ hybridization and microarray-based gen-
omic profiling were thus concordant in 13 of the 15 (87%)
successful in situ hybridizations. These cases all involved
the detection of a trisomy (cases 4893, 4895, 4522) or the
losses of whole chromosomes 5 and 7 using FISH probe
sets based on two probes in different colors (cases 4519,
4898, 4896, 4523, 4520).
For assessment of the detection limit of the microarray
platform we have compared the genetic abnormalities as
identified by microarray-based genomic profiling with
those as determined by FISH on the same bone marrow
biopsy. Abnormalities present in more than 18% of the
cells as determined by FISH were readily detected by
microarray, including 3 cases with a trisomy 8 (cases
4522 (18%), 4895 (23%) and 4893 (50%)), 3 patients with
del(5q) (cases 4521 (19%), 4523 (29%) and 4520 (40%)) 2
patients with del(20q) (cases 4522 (32%) and 4894
(77%)) and 5 patients with loss of chromosome 7 (cases
4519 (44%), 4898 (50%), 4896 (50%), 4523 (46%) and
4520 (61%)).
Comparison of microarray-based genomic profiling and
karyotyping
In all 21 patients with successful karyotyping on
the bone marrow aspirates microarray-based genomic
profiling was successfully performed on the bone mar-
row biopsies (Table 1). No significant difference in
genomic aberrations was observed between the MDS pa-
tients without (group 1) and with (group 2) fibrotic bone
marrow. In 7 (pseudo) diploid patients (group 3) CNA
were neither demonstrated by microarray-based gen-
omic profiling nor by karyotyping. Conventional karyo-
typing on two patients revealed the presence of balanced
genomic abnormalities, which as expected were not de-
tected by microarray-based genomic profiling. One case
(4892) without CNA involved the balanced t(3;3)(q21;q26),
and in the other case (4523) the t(4;17;20) was
present as additional abnormality. In seven patients the
CNA obtained by microarray-based genomic profiling and
karyotyping were exactly identical. In five other cases with
complex karyotypes (4896, 4522, 4899, 4520 and 4521)
there was no exact match between microarray-based
genomic profiling and karyotyping (Figure 2). However,
the discrepancy could be explained by the presence of
marker chromosomes which are (in part) derived from
missing chromosomes. In four of these patients (4522,
4899, 4520 and 4521) the loss of a chromosome or
chromosome segment and the presence of marker chro-
mosomes could be correlated with complex abnormal
array profiles of the corresponding chromosomes or
chromosome segments (Figure 2). In addition, all cases
involved a so-called composite karyotype, indicating the
presence of clonal heterogeneity. Due to clonal hetero-
geneity chromosome abnormalities may be present in a
small fraction of the cells and remain undetected by
microarray-based genomic profiling. One of the patients
(case 4521) harbored a focal 12-Mb loss involving the
4q24 region which contains the in MDS patients recur-
rently mutated TET2 gene [11], which was most likely
missed by karyotyping due to its size below the cytogen-
etic resolution (Figure 2). In two patients there was
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a discrepancy between karyotyping and microarray-
based genomic profiling. In one of these patients (case
4519) next to the del (5q) and loss of chromosome 7 as
observed by karyotyping, additional genetic abnor-
malities were observed by microarray profiling. In this
patient the microarray analysis was performed on a
sample obtained 5 months later than the sample used
for karyotyping, and might reflect the disease progres-
sion that was also demonstrated by histological and
cytological analysis in this patient. The discrepancy in
patient 4903 with a complex abnormal karyotype in the
aspirate and a normal microarray-based genomic pro-
file derived from the bone marrow biopsies may be
explained by the sparse hematopoiesis present in the
bone marrow biopsy of this patient, possibly resulting
in a DNA-sample consisting of predominantly non-
hematopoietic cells.
Discussion
Currently karyotyping is the gold standard for the detec-
tion of prognostic relevant chromosomal aberrations in
MDS [1,2]. However, its application is limited to dividing
cells obtained from bone marrow aspirates. In MDS pa-
tients with fibrotic bone marrow, the marrow aspirate
sample is often not representative (dry tap), and thus not
suitable for karyotyping [3,4]. Although challenging, ana-
lysis of bone marrow biopsies by FISH or microarray-
based genomic profiling could represent an alternative
approach for detection of genetic abnormalities in these
MDS cases with fibrotic bone marrow.
Numerous studies have demonstrated that FISH and
microarray-based genomic profiling on cells obtained
from bone marrow aspirates can identify genetic abnor-
malities [13,17-19]. However, despite the importance of
the use of bone marrow biopsies for the diagnosis of
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Figure 1 Trisomy 8 detected by Chromogenic in situ hybridization, karyotyping and microarray-based genomic profiling. Chromogenic in situ
hybridization with probe for centromere of chromosome 8 (panel A), microarray-based genomic profile (panel B) and karyotype (panel C) of
patient 4895, all indicating a trisomy 8.
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hematological malignancies [20,21], the application of
FISH on bone marrow biopsies has been barely investi-
gated [5-8,22] and the application of microarray-based
genomic profiling not at all. This may be related to
technical limitations as a poor DNA quality due to
DNA degradation during FFPE fixation, decalcification
and tissue processing [22,23], resulting in relatively
noisy array profiles [24,25]. Recently optimized sample
preparation approaches involving the fixation and de-
calcification process, the use of Qiagen DNA extraction
kit, and improved data analysis methods, have been
recommended to improve the detection of CNA by
genomic arrays on FFPE samples [24]. We have opti-
mized the fixation and decalcification procedure.
Despite these adaptations, we had to set the threshold
at 10 Mb for the identification of CNA, which is much
higher than required for high-molecular weight DNAs
obtained from bone marrow aspirates or peripheral blood
[26,27]. In addition the threshold for chromosome 19 ab-
normalities was increased to 30 Mb since GC-rich regions,
which are abundantly present on chromosome 19, are less
sensitive to DNA degradation (occurring in FFPE sam-
ples), leading to a more efficient PCR amplification and
hence higher signal intensity. The recently introduced
Figure 2 Comparison of karyotyping and microarray-based profiling in two patients with complex karyotypes. Karyotypes and microarray-based
genomic profiles from patient 4521 (panel A and B) and 4899 (panel C and D). CNA observed with microarray-based genomic profiling are marked by
arrows, including a 12 Mb focal loss of chromosome 4q24q26 (blue arrow).
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OncoScan array platform (Affymetrix) with the use of the
molecular inversion probe strategy has shown to perform
well with degraded DNA samples obtained from FFPE
specimens [28-30].
We have evaluated the diagnostic power and limit of
detection of microarray-based genomic profiling com-
pared to FISH and Chromogenic in situ hybridizations
on bone marrow biopsies. In 13 of the 15 successful in
situ hybridizations concordant results were obtained by
in situ hybridization and microarray-based genomic pro-
filing (Table 1). In two other cases (4896 and 4518) in
situ hybridization resulted in a false positive identified
abnormality. In these two cases in situ hybridization was
based on a single probe and suggested loss of chromo-
some segments (deletion 7q and loss of chromosome 8
respectively), which was not observed by microarray-
based genomic profiling and karyotyping. As noted by
others, the reliable detection of chromosome loss by
FISH is difficult, since nuclei of cells in tissue sections
are often sectioned [5]. In addition, the identification of
balanced rearrangements and gain of chromosomes by
FISH in tissue sections is more straight forward to detect
because of a simpler probe configuration. This was con-
firmed in the present study were we have identified all
three patients with a trisomy 8 by in situ hybridization
correctly. Furthermore, the applied microarray platform
exhibited a high limit of detection, i.e., CNAs present in
at least 18% of the cells as determined by FISH could
unambiguously be detected.
Microarray-based genomic profiling of non-fibrotic
as well as fibrotic bone marrow biopsy samples demon-
strated a high concordance with karyotyping on bone
marrow aspirates, and discrepancies between both
approaches could be explained by the complex karyo-
types, the presence of marker chromosomes, the pres-
ence of balanced translocations, clonal heterogeneity or
progression of the MDS. The only exception is a cyto-
genetically abnormal patient with a normal array pro-
file (case 4903). The discrepancy may be explained by
the sparse hematopoiesis in the biopsy, resulting in too
few malignant cells present for microarray analysis,
while cell culture for karyotyping, selective growth of
aberrant blasts could have enabled detection of the
cytogenetic aberrancies.
One important benefit of microarray-based genomic
profiling as compared to FISH is its ability to detect
additional chromosomal aberrations not detected by tar-
geted probe-based assay. In four of the five patients with
additional genetic abnormalities as compared to in situ
hybridization, the microarray profile was indicative for a
so-called complex karyotype which is associated with an
adverse prognosis [2,31]. In addition a focal loss on
chromosome 4q24q26 region containing the TET2 gene
as demonstrated by microarray-based genomic profiling
in case 4521 could not be observed by karyotyping be-
cause it was below the level of cytogenetic resolution.
The protein encoded by the TET2 gene plays a key role
epigenetic modification of the genome by DNA demeth-
ylation. The identification of this focal loss of the TET2
gene is of clinical relevance since it has been demon-
strated that this is a recurrent genetic abnormality in
MDS patients [11].
Conclusions
Our work represents the first genome wide microarray
approach for the analysis for CNA in bone marrow
biopsy samples in MDS patients. This is of clinical rele-
vance for MDS patients with fibrotic bone marrows in
whom cytogenetic data are lacking. In these patients
microarray is able to identify cytogenetic abnormalities
which are important parameters for the (revised) inter-
national prognostic scoring system for MDS patients.
We demonstrate a high concordance of karyotyping on
bone marrow aspirates and microarray-based genomic
profiling on both non-fibrotic and fibrotic bone marrow
biopsies in MDS patients. Although in situ hybridization
can be applied to bone marrow biopsies, it is important
to note that in situ hybridization for losses of chromo-
somes or chromosome segments may be misinterpreted
due to technical limitations. Therefore this study demon-
strates in MDS cases with failure to acquire a representa-
tive bone marrow aspirate that microarray-based genomic
profiling eventually complemented with FISH for balanced
prognostic relevant abnormalities (eg. 3q26/MECOM
rearrangements) is a valid alternative approach to
obtain information on clinical relevant cytogenetic
abnormalities.
Methods
Patients
Twenty-six bone marrow biopsies from MDS patients
with a successful cytogenetic result, were initially se-
lected from the hospital archive. Of these 26 samples, 5
were excluded because of several reasons (as described
under Results). For the remaining 19 MDS cases and 2
cases with a reactive non-fibrotic bone marrow, a good-
quality microarray-based genomic profile was obtained,
and these patients were further evaluated in this study.
Seven MDS patients were selected because of an abnor-
mal karyotype as determined by conventional cytogenet-
ics on a simultaneous bone marrow aspirate (group 1).
Seven other patients were selected because they had an
abnormal karyotype and extensive fibrosis in the bone
marrow biopsy (fibrosis grade 2/3 or 3/3) (group 2).
Another 4 MDS, 1 AML and 2 reactive non-fibrotic
BMB without copy number alterations (CNA) as deter-
mined by karyotyping were selected as controls (group 3)
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(Table 1). The diagnosis of MDS was made by combining
histology, cytomorphology, clinical and cytogenetic data.
The bone marrow biopsies were fixed in Burckhardt
pH 7.4 at room temperature, followed by decalcification
in EDTA 10% pH 7.2 (room temperature) during 48 hrs.
Post-decalcification tissue processing consisted of dehy-
dration and paraffin embedding using either the Pathos
Rapid Microwave Histoprocessor (Milestone, Sorisole,
Italy) or the Shandon™ Excelsior™ ES Tissue Processor
(Thermo Scientific, Waltham, MA, USA).
This study was approved by the institutional review
board of the Radboud university medical center and in
accord with the Helsinki Declaration 1975, as revised
in 2008.
Karyotyping
Hematopoietic cells from bone marrow aspirates were cul-
tured and harvested for cytogenetic analysis by established
methods. Chromosome aberrations were described ac-
cording to guidelines of an International System for
Human Cytogenetic Nomenclature [15].
In situ hybridization
Fluorescence in situ hybridization (FISH) was performed
based on the protocol described by Gerr et al. [32]. Briefly,
4 μm tissue sections were pretreated with 10 mM sodium-
citrate pH 6.0 using a microwave, digested with 200 U/ml
pepsin/0.01 M HCl and fixated in 1% buffered formalde-
hyde. The commercially available probes LSI D7S485/CEP
7 (7q31/centromere 7), LSI EGR1/D5S721/D5S23 (5q31/
5q15.2) and LSI D20S108 (20q12) (Abbott Molecular,
Des Plaines, Illinois, USA) were used according to the
manufacturer’s specifications. Signals were counted using
an fluorescence microscope (DM4000B, Leica, Rijswijk,
Netherlands). The homemade probe CEP 8 (D8Z2) la-
beled with biotin was detected using immunohisto-
chemical staining (Chromogenic in situ hybridization).
The immunohistochemical staining was performed by
successive incubations with mouse-anti-biotine (Vector,
Vector Laboratories, Burlingame, CA, USA), Bright-
Vision Poly-HRP-Anti Ms/Rb/Rt IgG (Immunologic,
Duiven, The Netherlands), and Bright-DAB (Immunologic,
Duiven, The Netherlands) according to manufacturer’s
specifications. Interpretation was performed as described
[32] and least 100 cells were evaluated per case.
DNA extraction and microarray-based genomic profiling
5–10 μm paraffin-embedded tissue sections were used
to extract DNA using proteinase K treatment step ac-
cording to the standard protocol. Subsequently, the
DNA was treated with RNAase A (Qiagen, Venlo, The
Netherlands) and was affinity-purified using QIAamp
MinElute Columns (Qiagen, Venlo, The Netherlands).
DNA sample concentration and quality were assessed by
spectrophotometry and by PCR-amplification using the
BIOMED-2 Control gene primer set [33]. Affinity-
purified DNA samples (100 ng) that were able to amplify
control gene fragments of 200 bp or more were used for
whole genome amplification (ENZO diagnostics Inc.,
Farmingdale, NY, USA) for subsequent microarray pro-
filing. Microarray-based genomic profiling was carried
out using a Nimblegen human CNV 3 × 720 K whole-
genome tilling array (Roche NimbleGen Inc., Madison,
WI, USA) according to the manufacturer’s protocols.
Each sample was referenced against a sex-matched non-
tumor bone marrow biopsy sample. Data were analyzed
using the NEXUS version 5 (Biodiscovery, Hawthorne,
CA, USA) software package. The quality of the array
hybridization was monitored by determination of the
variance of difference between adjacent log ratio’s after
excluding the outliers (Nexus QC score). Array hybrid-
izations with a Nexus QC above 0.4 were excluded for
further analysis. Abnormal segments were identified by
the FASST2 segmentation algorithm with a significance
threshold of 1.0 E-20, a maximum probe spacing of
1 Mb, and a minimum number of 10 probes for a seg-
ment. The log2 thresholds were set to 0.4, 0.12, −0.18,
and −0.6 to distinguish between high copy gains, single
copy gains, single copy losses, and homozygous losses
respectively. Only segments fulfilling the above criteria
and >10 Mb were identified as CNA.
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